Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
The LTF-305 study has completed enrollment and is scheduled to be closed. All patients participating in this study have discontinued from follow-up or have been transferred into the GC-LTFU-001 study for further observation (similar to time frames established in the LTF-305).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of written informed consent for this study by subjects
Were administered bb2121 in the parent clinical study
Able to comply with the study requirements
You may not be if
Subject has disease progression AND subject has undetectable VCN (\<0.0003 vector copies per diploid genome) in peripheral blood cells for 2 consecutive measurements at least 1 month apart, at least 12 months after drug product infusion
Clareo Health | Longterm Follow-up of Subjects Treated With bb2121
